|
|
Aerosolized Cyclosporine Shows Significant Results in Chronic Rejection of Allogenic Lung Transplants
Mar 24, 2005, 09:22, Reviewed by: Dr.
|
|
The aerosolized cyclosporine NDA (50-799) includes a single pivotal trial that showed significant results in chronic rejection of allogenic lung transplants, but not in acute rejection.
|
By Akanksha, Pharmacology Correspondent,
The Pulmonary-Allergy Drugs Advisory Committee will review Chiron�s aerosolized cyclosporine Pulminiq for lung transplantation June 6.
The committee discussion likely will focus on additional analyses of pivotal data.
Chiron confirmed that FDA extended aerosolized cyclosporine�s priority review deadline of April 15 by 90 days following the firm�s submission of additional analyses earlier this year.
The company had been expecting the 90-day extension following FDA�s request for further analysis of the NDA�s pivotal trial.
The aerosolized cyclosporine NDA (50-799) includes a single pivotal trial that showed significant results in chronic rejection of allogenic lung transplants, but not in acute rejection.
Chiron is seeking approval for use of aerosolized cyclosporine in combination with standard immunosuppressive therapy to increase survival and prevent chronic rejection in patients receiving allogenic lung transplants.
This would be the first immunosuppresant approved for the indication, Chiron said. 
- FDA Advisory Committee
FDA Advisory Committee
This meeting will be held June 6, 2005 at the CDER advisory committee conference room in Rockville, Md. beginning at 8 a.m.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
